Ataxia–Telangiectasia (A-T)
Introduction
Ataxia–telangiectasia (A-T) as a rare autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased predisposition to malignancies. The condition, first described by Louis–Bar, manifests in early childhood with motor coordination difficulties, which gradually worsen over time. A–T is a multisystem disorder, affecting the nervous system, immune system, and other organs and presents with significant clinical heterogeneity.
Genetics
The disorder is caused by biallelic mutation in the ATM gene (Ataxia-Telangiectasia Mutated gene), located on chromosome 11q22–q23. The ATM gene encodes a serine/threonine protein kinase that plays an important role in DNA double-strand break repair, cell cycle regulation, and the cellular response to oxidative stress. Loss-of-function mutations in the ATM gene result in defective DNA damage response, leading to genomic instability, progressive neuronal loss, and increased susceptibility to malignancy. A–T is inherited in an autosomal recessive pattern, meaning that both alleles carry pathogenic variants, although heterozygous carriers may have a slightly increased cancer risk.
Epidemiology
Ataxia-telangiectasia, as mentioned above, is rare, with an estimated prevalence of 1 in 40,000–100,000 live births worldwide. The disease affects both sexes equally and occurs in all ethnic groups. Consanguinity increases the risk of occurrence in certain populations due to autosomal recessive inheritance. The clinical symptoms usually appear during infancy or early childhood, and early suspicion is often based on neurological symptoms and the presence of telangiectasias.
Pathophysiology
The pathophysiology of A-T is primarily characterized by defective DNA repair and progressive neurodegeneration. ATM gene impairs the detection and repair of double-strand DNA breaks, leading to genomic instability. In the central nervous system, Purkinje cells and other cerebellar neurons are particularly vulnerable, which leads to progressive cerebellar atrophy and, as a clinical result, ataxia. Dysfunction of the immune system arises from impaired lymphocyte development and DNA recombination, both of which contribute to immunodeficiency. The genomic instability also underlies the high susceptibility to malignancies, particularly lymphoid tumors.
Additionally, oxidative stress, abnormal cell signaling, and premature cellular senescence contribute to other systemic manifestations of the disease.
Clinical Manifestations
The main feature of A-T is progressive cerebellar ataxia, typically evident in early childhood, as well as gait disturbances and poor coordination. Other neurological signs include dysarthria, oculomotor apraxia, and impaired fine motor skills. Oculocutaneous telangiectasias, more obvious in the conjunctiva and sun-exposed areas of the skin, appear between the ages of 3 and 6 years. Immunodeficiency, primarily involving both humoral and cellular components, leads to recurrent sinopulmonary infections.
Individuals with A-T also exhibit endocrine abnormalities such as insulin resistance and premature aging. Importantly, patients are at significantly increased risk of malignancies, especially lymphoid cancers, and are highly sensitive to ionizing radiation.
Diagnosis
Diagnosis of A-T is based on clinical features and laboratory findings, and confirmed by genetic testing. Characteristic symptoms include progressive cerebellar ataxia, telangiectasias, and recurrent infections. Elevated serum alpha-fetoprotein level is a diagnostic biochemical finding. However, immunological evaluation often reveals lymphopenia and impaired immunoglobulin production. MRI of the brain typically shows cerebellar atrophy, particularly in the vermis. Confirmation is achieved by identifying biallelic pathogenic variants in the ATM gene. Early diagnosis is crucial for the implementation of supportive care, cancer surveillance, and genetic counseling.
Treatment
There is currently no curative treatment for A-T, and management is primarily supportive. Physical and occupational therapy are essential for maintaining of mobility, balance, and functional independence. Immunodeficiency is treated by infection prophylaxis, immunoglobulin replacement, and prompt antibiotic treatment of infections. Surveillance for malignancies, particularly lymphoid cancers, is essential, and the focus must be on avoiding radiation (CT scans and X-rays). Treatment of pulmonary complications, endocrine disorders, and nutritional deficits improves quality of life. Genetic counseling is essential for families, and emerging therapies targeting DNA repair pathways and oxidative stress are under investigation.
Prognosis
The prognosis of A-T is variable but generally poor due to progressive neurodegeneration, immunodeficiency, and the elevated risk of malignancy. Most individuals experience significant motor disability by adolescence and are prone to chronic pulmonary complications. Life expectancy is reduced, with many patients surviving into the second or third decade of life. Early diagnosis, comprehensive supportive care, and careful management of infections and malignancies can improve quality of life and delay complications, although the disease remains life-limiting.
